Groupama Asset Managment Sells 6,249 Shares of Edwards Lifesciences Co. (NYSE:EW)

Groupama Asset Managment lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 18.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,809 shares of the medical research company's stock after selling 6,249 shares during the period. Groupama Asset Managment's holdings in Edwards Lifesciences were worth $2,065,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after acquiring an additional 126,194 shares in the last quarter. National Bank of Canada FI boosted its holdings in Edwards Lifesciences by 9.4% during the fourth quarter. National Bank of Canada FI now owns 332,387 shares of the medical research company's stock worth $24,607,000 after buying an additional 28,534 shares in the last quarter. HighPoint Advisor Group LLC lifted its position in shares of Edwards Lifesciences by 5.1% in the 4th quarter. HighPoint Advisor Group LLC now owns 11,980 shares of the medical research company's stock valued at $850,000 after acquiring an additional 577 shares in the last quarter. Summit Financial LLC grew its holdings in shares of Edwards Lifesciences by 5.0% during the 4th quarter. Summit Financial LLC now owns 6,076 shares of the medical research company's stock valued at $450,000 after acquiring an additional 288 shares in the last quarter. Finally, AIA Group Ltd raised its holdings in Edwards Lifesciences by 24.2% during the fourth quarter. AIA Group Ltd now owns 930,933 shares of the medical research company's stock valued at $68,917,000 after buying an additional 181,409 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on EW shares. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Citigroup increased their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. Evercore ISI cut their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Finally, Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Stock Down 0.9 %

Shares of NYSE:EW traded down $0.65 during trading on Monday, reaching $68.71. The stock had a trading volume of 2,292,137 shares, compared to its average volume of 4,837,067. The firm's 50-day simple moving average is $71.74 and its 200 day simple moving average is $70.66. The company has a market capitalization of $40.39 billion, a P/E ratio of 9.81, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business's stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bernard J. Zovighian sold 6,164 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares of the company's stock, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,553 shares of company stock valued at $4,513,064 over the last three months. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.